参考文献/References:
[1] Schon MP,Boehncke WH.Psoriasis[J].N Engl J M-ed,2005(352):1899-1912.
[2] David A,Jennifer E,Gregory K,et al.The emerging role of interleukin-17 in the pathogenesis of psoriasis:preclinical and clinical findings[J].J Invest Dermatol,2013,133(1):17-26.
[3] Caruso R,Botti E,Sarra M,et al.Involvement of interleukin 21 in the epidermel hyperplasia of psoriasis[J].Nat Med,2009,15(9):1013-1015.
[4] 任兴斌,诸葛宝忠,季海生.湿疹患者外周血CD4+CD25+FOXP3+调节性T细胞和血清IL-4,IL-10,TGF-β检测及临床研究[J].现代检验医学杂志,2010,25(3):131-133,136.
Ren XB,Zhuge BZ,Ji HS.Detection of nTreg cell and IL-4,IL-10,TGF-β in peripheral blood of eczema patients and its clinical significance[J].J Mod Lab Med,2010,25(3):131-133,136.
[5] 赵 辨.中国临床皮肤病学[M].南京:江苏科学技术出版社,2010:762-764.
Zhao B.Chinese Clinical Dermatology[M].Nanjing:Jiangsu Scienceand Technology Press,2010:762-764.
[6] Fadzil MH,Ihtatho D,Affandi AM,et al.Area asse-ssment of psoriasis lesions for PASI scoring[J].J Med Eng Technol,2009,33(6):426-436.
[7] Ahmad Fadzil MH,Ihtatho D,Affandi AM,et al.Objective assessment of psoriasis erythema for PASI scoring[J].J Med Eng Technol,2009,33(7):516-524.
[8] Schmitz I,Schneider C,Fr(¨overo)hlich A,et al.IL-21 restricts virus-driven Treg cell expansion in chronic LCMV infection[J].PLoS Pathogens,2013,9(5):1003362.
[9] Wei L,Laurence A,Elias KM,et al.IL-21 is produced by Th17 cells anddrives IL-17 production in a STAT3-dependent-manner[J].J Biol Chem,2007,282(48):34605-34610.
[10] Numerof RP,Asadullah K.Cytokine and anti-cyto-kine therapiesfor psoriasis and atopic dermatitis[J].Bio Drugs,2006,20(2):93-103.
[11] Carter NA,Rosser EC,Mauri C.Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses,induction of T regulatory type1 cells and reduction of collagen-induced arthritis[J].Arthritis Res Ther,2012,14(1):R32.
[12] Asadullah K,Friedrich M,Hanneken S,et al.Effects of systemic interleukin-10 therapy on psoriatic skin lesions:histologic,immunohistologic,and molecular biology findings[J].J Invest Dermatol,2011,116(5):721-727.
相似文献/References:
[1]马小娜,张 辉,王宏东,等.银屑病患者血浆可溶性尿激酶型纤溶酶原激活物受体(suPAR)与疾病严重程度的关联性研究[J].现代检验医学杂志,2017,32(02):41.[doi:10.3969/j.issn.1671-7414.2017.02.011]
MA Xiao-na,ZHANG Hui,WANG Hong-dong,et al.Correlation between Plasma-soluble Urokinase Plasminogen Activator
Receptor(suPAR)Levels and Disease Severity in Psoriasis Patients[J].Journal of Modern Laboratory Medicine,2017,32(02):41.[doi:10.3969/j.issn.1671-7414.2017.02.011]